Table 2. Publications on HCC relapse in patients after HCC treatment with curative intent (resection. local ablation. liver transplantation).
| First author (reference) |
Number of patients |
Median time HCC treatment until DAA therapy (months) |
Median follow-up after DAA therapy (months) |
Relapse rate (relapse rate per 100 person-years) |
Median time DAA therapy until recurrence (months) |
| Reig (24) FP |
58 | 11.2 | 5.7 | 27.6% | 3.5 |
| Conti (20) FP |
59 | 12.5 | 6 | 28.8% | 3.3 |
| Yang (25) LTE |
28 84*1 |
? | ? | 27.8% 9.5% |
4/5 <6 months 2/6 <6 months |
| Zavaglia (26) LTE |
31 | 19.3 | 8 | 3.2% | ? |
| Torres (e1) LTE |
8 | 7.5 | 12 | 0% | ? |
| Zeng (e2) LTE |
10 | ? | 15 | 0% | ? |
| Minami (27) LTE |
27 38*2 861*1 |
5.8 5.4 ? |
15.6 | 21.1%; 29.8%*3 26.3%; 52.9%*3 30.5%; 61.0%*3 |
? |
| Pol (CUPILT substudy)*4 (28) FP |
314 | 67 | ? | 2.2% | 7.0 |
| Pol (CirVir substudy)*4 (28) FP |
13 66*1 |
3 | ? | 7.7% (1.73) 47.0% (1.11) |
? |
| Pol (Hepather substudy)*4 (28) FP |
189 78*1 |
22.8 19.2 |
20.2 26.1 |
12.7 % (0.73) 20.5% (0.66) |
? |
*1untreated control group; *2 interferon therapy; *3 1- and 2-year relapse rates; *4 subgroups of the ANRS Collaborative Study Group on Hepatocellular Carcinoma (28);
DAA, direct acting antivirals; HCC, hepatocellular carcinoma; LTE, letter to the editor; FP, full publication